"Protein Engineering" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes.
| Descriptor ID |
D015202
|
| MeSH Number(s) |
E05.393.420.601
|
| Concept/Terms |
Protein Engineering- Protein Engineering
- Engineering, Protein
- Genetic Engineering, Protein
- Engineering, Protein Genetic
- Protein Genetic Engineering
- Proteins, Genetic Engineering
- Genetic Engineering of Proteins
|
Below are MeSH descriptors whose meaning is more general than "Protein Engineering".
Below are MeSH descriptors whose meaning is more specific than "Protein Engineering".
This graph shows the total number of publications written about "Protein Engineering" by people in this website by year, and whether "Protein Engineering" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Engineering" by people in Profiles.
-
Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
-
Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat Med. 2020 03; 26(3):430-440.
-
Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. Retrovirology. 2019 11 08; 16(1):31.
-
Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
-
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18; 41(6):909-18.
-
Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.